• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Abstract B45: c-MYC is a potential therapeutic target for cisplatin-resistant ovarian cancer
Ovarian cancer accounts for approximately 3% of all cancers in women. However, it is the deadliest cancer of the female reproductive system. Due to its non-specific symptoms, ovarian cancer is diagnosed at advanced stages of the disease. The most common standard treatment for advanced ovarian cancer is the platinum-based drugs such as cisplatin. However, over 70% of women relapse due to chemoresistance. Several mechanisms of cisplatin resistance have been described. However, the exact mechanism is not known. Evidence indicates that activation of the transcription factor c-MYC and its regulated genes could be involved in su...
Source: Molecular Cancer Research - October 18, 2015 Category: Cancer & Oncology Authors: Vivas-Mejia, P. E., Reyes, j., Sood, A. K. Tags: Therapeutic Translation: Poster Presentations - Proffered Abstracts Source Type: research